

CURRICULUM VITAE

Matthew Cooper, M.D.
Professor of Surgery
Georgetown University School of Medicine
Director, Kidney and Pancreas Transplantation
Medstar Georgetown Transplant Institute

Date: August 2014

Work Address: Medstar Georgetown Transplant Institute
Medstar Georgetown University Hospital
3800 Reservoir Rd., NW
2-Main
Washington, DC 20007
Office: 202-444-0753
Fax: 877-680-8193
Matthew.Cooper@gunet.georgetown.edu

Current Appointments:

Director, Kidney and Pancreas Transplantation
-Medstar Georgetown Transplant Institute
-Medstar Georgetown Transplant Institute at Washington Hospital Center
-Children's National Medical Center

Medical Director Peri-operative Services, Georgetown University Hospital
Washington, DC

Education

Undergraduate: University of Scranton
Scranton, Pennsylvania
Dates Attended: 8/1986- 5/1990
Degree: Bachelor of Science in Biochemistry
Minors: Spanish and Philosophy
Undergraduate Thesis: Carbon-Hydrogen Bond Activation

Graduate/Professional: Georgetown University School of Medicine
Washington, D.C.
Dates Attended: 8/1990- 6/1994
Degree: Doctor of Medicine

Post Graduate Education and Training

Residency: Medical College of Wisconsin Affiliated Hospitals
Milwaukee, Wisconsin
Residency in General Surgery
Dates Attended: 7/1994- 6/2000

Postdoctoral Training: Johns Hopkins Hospital
Baltimore, Maryland
Fellow in Transplant Surgery
Dates: 7/2000- 6/2002

Research: Medical College of Wisconsin
Milwaukee, Wisconsin
Division of Transplant Surgery
Dates: 7/1996- 6/1997

Certification

1996 USMLE, Step I, II, III #4-000-981-3

2001 Qualifying Examination
American Board of Surgery

2003 Certifying Examination
American Board of Surgery #48586

Medical Licensure

1994-2000 Wisconsin Medical License #37971

2000- Maryland Medical License #D0056067

2004-2013 Delaware Medical License #C1-0007439

2012- Washington, DC Medical License #MD040706

2013 - Virginia Medical License #0101254579

Professional Experience

2000-2002 Instructor of Surgery, The Johns Hopkins University School of Medicine,
Baltimore, MD

2002-2005 Assistant Professor of Surgery, The Johns Hopkins University School of
Medicine, Baltimore, MD

2005-2012 Associate Professor of Surgery, University of Maryland School of Medicine, Baltimore, MD

2012- Professor of Surgery, Georgetown University School of Medicine, Washington, DC

Hospital Appointments

2002 - 2005 Johns Hopkins Hospital, Baltimore, MD

2005 - 2012 University of Maryland Medical System, Baltimore, MD

2012 - Medstar Georgetown University Hospital, Washington, DC

2012 - Medstar Washington Hospital Center, Washington, DC

2012- Children's National Medical Center, Washington, DC

Study Sections/Steering Committees

2008, 2009 HRSA-08-075
Clinical Interventions to Increase Organ Procurement
Washington, DC
Role: Grant Reviewer

Professional Society Memberships

Member, American Medical Association
Member, American Society of Transplant Surgeons
Member, American Society of Transplant Physicians
Member, The Transplantation Society
Member, International Liver Transplant Society
Member, DC Chapter of the American College of Surgeons
Member, Association of Academic Surgeons
Member, Association for Surgical Education
Member, American College of Surgeons

Honors and Awards

1990 Magna cum laude – University of Scranton

1990 Excellence in Biochemistry – University of Scranton

1990 National Jesuit Alumni Society Award for Loyalty and Service

1994 National Jesuit Leadership and Service Award – Georgetown University

Honors and Awards (Continued)

1994-1995	Junior Surgical Resident of the Year – Medical College of Wisconsin
1997	First Place – Milwaukee Academy of Surgeons Resident Research Presentation Night
1997	American Trauma Society’s Young Investigator Award
1997	First Place, Basic Science Research – Wisconsin Surgical Society
1998	First Place – Medical College of Wisconsin Robert E. Condon Research Awards
1999-2000	Chief Administrative Resident – Medical College of Wisconsin
2007-2008	Surgical Educator of the Year – University of Maryland Department of Surgery
2011-2014	Washington Post Magazine’s Super Doctors
2011-2013	Baltimore Magazines’ Top Docs

Administrative Service

Institutional Appointments:

2003-2005	Johns Hopkins Hospital Performance Improvement Committee
2003-2005	Johns Hopkins Hospital OR Advisory Committee – Transplant/Vascular/Trauma
2004-2005	Johns Hopkins School of Medicine Education Committee
2004-2005	Johns Hopkins School of Medicine Clinical Research Steering Committee
2004-2005	Johns Hopkins School of Medicine Medical School Council – Dept. of Surgery Representative
2004-2005	Johns Hopkins Hospital DVT Collaborative – Divisional Chair
2006-2012	University of Maryland Division of Transplantation Resident and Medical Student Educational Coordinator

Institutional Appointments (Continued):

2007- 2009	University of Maryland School of Medicine Council – Department of Surgery Representative
2008-2012	University of Maryland Division of Transplantation – Chair, Living Donor Ethics Committee
2008-2012	University of Maryland Division of Transplantation – “Ask the Expert” web-based patient site
2009-2012	University of Maryland Department of Surgery Peer Review Committee
2010-2012	University of Maryland Department of Surgery Medical Student Grading Committee
2011-2012	University of Maryland Medical Center Co-worker Civility Committee
2012-	Georgetown University Hospital/Disney Institute – Patient Experience, Physician Engagement Group
2012-	GUH Organ Donation Committee
2013-	Medical Director, MGUH Operating Rooms
2014-	MGUH Peri-operative Governance Council
2014-	Clinical Resource Allocation Group – MGUH
2014-	MGUH OR Safety Committee

Local and National Service:

2003-2008	Scientific Advisory Board, Genzyme Pharmaceuticals
2003-	Scientific Advisory Board, Novartis Pharmaceuticals
2004-	Ad Hoc Reviewer, <i>Archives of Surgery</i>
2004	Reviewer, Baltimore Academy of Surgery Resident Research Presentations
2004-2006	Member, OPTN/UNOS Living Donor Region 2 Representative

Local and National Service (Continued):

2006-2009 Member, Scientific Studies Committee, American Society of Transplant Surgeons

2006- Member, OPTN/UNOS Subcommittee, Kidney Paired Donation Program

2006-2009 Reviewer, National Kidney Foundation of Maryland Research Grants

2006-2009 Member, OPTN/UNOS Subcommittee, Living Donor Data

2008- Reviewer, American Transplant Congress Abstract Submissions

2007-2009 Data Safety Monitoring Board, Y's Therapeutics

2008 Reviewer, ASTS Student Mentor Awards

2008-2010 Chair, UNOS Living Donor Committee

2008-2011 Member, ASTS Fellow's Curriculum Committee

2008- 2010 Clinical Advisory Board/ Data Safety Monitoring Board
Quark Pharmaceuticals

2008- Ad Hoc Reviewer, *American Journal of Transplantation*

2008- Ad Hoc Reviewer, *Clinical Transplantation*

2008- Ad Hoc Reviewer, *Transplantation*

2009-2012 Vice-Chairman, Living Legacy OPO's Advisory Board of Trustees

2009-2013 Board Member, National Kidney Foundation of Maryland

2009-2012 Member, National Kidney Foundation End the Wait! Taskforce

2010- Member, National Kidney Foundation Public Policy Committee

2010-2012 Chairman, National Kidney Foundation of Maryland's Rappel for Kidney Health, Baltimore, MD

2010- Member, National Kidney Foundation's Living Donor Executive Council

Local and National Service (Continued):

2010 Steering Committee, Living Kidney Donor Follow-up: State of the Art and Future Directions, Crystal City, MD

2010- Ad Hoc Reviewer, *Immunotherapy*

2011-2012 Member, UNOS Living Donor Joint Society Working Group

2011 Member, ACOT Realignment Working Group

2011 Co-Chair, 2012 ATC Abstract Review Committee

2011 Program Committee, 2012 24th International Congress of the Transplantation Society

2012- American Transplant Congress Program Committee

2012-2014 Board Member, United Network of Organ Sharing

2012- Board Member, Washington Regional Transplant Community OPO

2012- Medical Steering Committee, National Capitol Area National Kidney Foundation

2012- Member, UNOS Kidney Paired Donation Joint Society Working Group

2013- Board Member, National Capitol Area National Kidney Foundation

2013- Board Member, American Foundation for Donation and Transplantation

2013 - Clinical Trial Steering Committee, Opsona Pharmaceuticals

2014- Steering Committee, AST Sponsored Best Practices in Living Donation

2014- Board Member, National Kidney Foundation

Educational Activities

Teaching:

Classroom Instruction:

2003- 3rd Year Surgical Clerkship Lecture
Abdominal Organ Transplantation
Vascular Access
Transplant Complications
45, 3rd Year Medical Students – 8 contact hours/yr

Clinical Instruction:

2003- Attending Physician In-patient Service
1 fellow, 2 residents, 1 intern, 2 jr. medical students
3 hours/day, 5 months/year

2003- Medical Student Instructor/Small group preceptor
4-5 medical students on weekly basis/quarter
Case presentations and patient-oriented instruction
1.5 hours/wk, 8 months/year

2003- Medical Student Mentor/Advisor
One-on-one advisor role to second-fourth year medical students with
particular interest in a surgical career
2 hours/month, 12 months/year

CME Instruction:

2003 ABC's of Renal Transplantation
Towson, MD
Course Director

2004 Incompatible Renal Transplantation: Solving the Puzzle
Baltimore, MD
Small-group leader

2005 Palliative Care: What Every Surgeon Needs to Know
Baltimore, MD
Invited lecturer – 'Educating the Resident in End-of-Life Issues'

2006 Symposium on Transplant and Dialysis Center Relationships: Promoting
the Partnership
Baltimore, MD
Invited lecturer – 'Expanded Criteria Donors'

CME Instruction (Continued):

- 2007 MPA as a Cornerstone Therapy in Immunosuppression
American Transplant Congress
San Francisco, CA
Invited lecturer – ‘The Importance of MPA Optimal Dose in Solid Organ Transplantation’
- 2007 Optimal MPA Dosing: The Key to Improved Long Term Graft Outcome
European Society of Transplantation
Prague, Check Slovakia
Moderator and Lecturer
- 2008 Maintaining Optimal MPA Dosing Following Kidney Transplantation
Milwaukee, WI
- 2008 Hot Topics in Kidney Transplantation
WEB-based/Teleconference
Invited Faculty
- 2010 Extending Allograft Function and Recipient Survival
Baltimore, MD
Pittsburgh, PA
Invited Lecturer - Management of Immunosuppression

Mentoring:

Advisees (House staff):

- | | |
|-----------------------------|---------------------------|
| Andrew Singer (2003-2005) | Jayne Locke (2003-2005) |
| Matthew Weiss (2004-2005) | Joseph Scalea (2007-2012) |
| Josephine Kweku (2008-2012) | Philip Brazio (2009-2012) |
| Julia Terhune (2010-2012) | Gabriel Ivey (2012 – |
| Sarah Carter (2012 – 2012) | Duncan Yoder (2012 -2014) |

Students

- | | |
|------------------------------|----------------------------------|
| Geoffrey Roelant (2005-2008) | Khayree Butler (2006-2008) |
| Gerald Gant (2006-2010) | Preetha Umamheswaran (2007-2008) |
| Josephine Kweku (2007-2008) | Joseph Jones (2007-2008) |
| Caroline Butler (2007-2009) | Keri Quinn (2008-2009) |
| Poornima Vanguri (2008-2009) | Andres Correa (2008-2010) |
| Burm Lee (2009-2010) | Veronica Bustillo (2009-2010) |
| Daniel Smith (2010-2012) | Catherine Njathi (2009-2011) |
| John Berquist (2010-2012) | Colin Powers (2011-2012) |

Grant Support

6/9/04 - 6/9/06

National Kidney Foundation of Maryland, Inc.

A cross-sectional study of African American living kidney donors to assess the risk for adverse renal outcomes

This is single-center, cross-sectional study designed to assess the risk of adverse renal and related risks in African American living kidney donors who donated at the University of Maryland between March 1996 and March 2002 as compared to non-African American living kidney donors.

Principle Investigator: Joseph Nogueira, MD

Role: Co-investigator

Total Direct Costs: \$10,000

6/9/04 - 6/9/06

National Kidney Foundation of Maryland, Inc.

A cross-sectional study of obese living kidney donors to assess the risk for adverse renal outcomes

This is single-center, cross sectional study designed to assess the risk of adverse renal and related risks in obese living kidney donors who donated at the University of Maryland between March 1996 and March 2002 as compared to non-obese living kidney donors from the same period.

Principle Investigator: Joseph Nogueira, MD

Role: Co-investigator

Total Direct Costs: \$8,500

7/25/07 - 7/27/09

University of Maryland Other Tobacco-Related Diseases Research Grant

A long-term follow-up pilot study of living kidney donors to assess patterns of smoking and to assess if obesity, African American race and smoking are associated with adverse health outcomes

This is single-center, cross-sectional study designed to (1) compile baseline medical and social information as well as pre-donation evaluation “process of care” data on a large cohort of our center’s live donor population, (2) provide data on the link between short-term perioperative smoking cessation and long-term abstinence, (3) provide important data on the adequacy of medical follow-up in live kidney donors, and (4) provide critical data on the health status of prior kidney donors that will help us better estimate the risks associated with obesity, race and smoking in live kidney donors.

Principle Investigator: Joseph Nogueira, MD

Role: Co-Investigator

Total Direct Costs: \$50,000

Grant Support (Continued):

1-08-CR-60

01/01/08 - 12/31/10

American Diabetes Association

Steroid Challenge and the Prediction of Post Transplant Diabetes Mellitus

The goal of this project is to determine if a prednisone modified oral glucose tolerance test performed prior to renal transplant in non-diabetic patients predicts who will develop post transplant diabetes mellitus.

Principle Investigator : Kristi Silver, MD

Role: Co-investigator

Total Direct Costs: \$516,462

Total Indirect Costs: \$77,469

Clinical Trial Support:

-Britol-Myers Squibb

12/21/2001- 6/24/2003

Open-label, randomized, controlled, multiple-dose study of efficacy and safety of BMS-224818 as Part of a Quadruple Drug Regimen in Renal Transplant Recipients

This protocol looks to assess the efficacy at 6 months of BMS-224818 versus CsA when used in combination with Cellcept, corticosteroids, and basiliximab using a non-inferiority design.

Role: PI

Total Direct Costs: \$245,000

-Fugisawa Healthcare

8/25/2003- 4/03/2005

Phase III, Randomized, Open-Label, Comparative, Multi-Center Study to assess the safety and efficacy of Prograf (tacrolimus) and Cellcept, Modified Release (MR) Tacrolimus and Cellcept, and Neoral and Cellcept in de novo Kidney Transplant Recipients

This study investigates the new once-a-day formulation of Tacrolimus versus standard twice dosing Tacrolimus and Neoral in first time kidney transplant recipients.

Role: PI

Direct Costs: \$174,160

-Genzyme Medical Corporation

1/12/2004- 11/18/2005

Randomized, Prospective, Phase II Study Comparing Thymoglobulin in a Rapid Discontinuation of Corticosteroids Protocol with standard corticosteroid therapy in Living Donor Renal Transplantation.

This protocol investigates the avoidance of steroid administration in living donor kidney transplant recipients utilizing polyclonal antibody induction therapy.

Role: PI

Total Direct Costs: \$130,000

Clinical Trial Support (Continued):

-Wyeth Pharmaceuticals

2/01/2004- 4/04/2005

Randomized open-Label Study to Compare the Safety and Efficacy of Two Different Sirolimus Regimens with a Tacrolimus and Mycophenolate Mofetil Regimen in de novo Renal Allograft Recipients.

This protocol investigates two varying immunosuppressive medication levels in order to determine efficacy with the avoidance of medication side effects versus a standard immunosuppressive regimen.

Role: PI

Total Direct Costs: \$106,299

-Novartis Pharmaceuticals

2/01/2004-6/30/2005

A prospective multicenter, open label, randomized study of the safety tolerability, and efficacy of Certican with Simulect, corticosteroids and lower levels versus higher levels of tacrolimus in de novo renal transplantation.

This protocol evaluates the use of an investigational antimetabolite and its cumulative effects with tacrolimus in order to determine and effective and safe medication administration dosage.

Role: PI

Total Direct Costs: \$72,660

-Roche Laboratories Inc

7/18/2004-6/30/2005

An open-label, prospective, randomized, controlled multi-center study assessing fixed dose vs. concentration controlled Cellcept regimens for patients following a single organ renal transplant in combination with full dose and reduced dose calcineurin inhibitors.

The purpose of this protocol is to compare the efficacy and the effects on renal function of a regimen of reduced concentration of calcineurin inhibitor and monitored Cellcept to a regimen of standard concentrations of calcineurin inhibitor and fixed-dose Cellcept.

Role: PI

Total Direct Costs: \$100,000

-Novartis Pharmaceuticals

10/01/2004-6/30/2005

A three-month, open-label, two cohort study to investigate the safety and tolerability of Myfortic in combination with Neoral or Tacrolimus in renal transplant recipients with GI intolerance. The objective of this study is to assess the tolerability of Myfortic in combination with CNIs as determined by gastrointestinal symptom rating scale (GSRS) after conversion from Cellcept within 3 months.

Role: PI

Total Direct Costs: \$130,000

Clinical Trial Support (Continued):

-Fugisawa Healthcare

11/21/2004-6/30/2005

A Phase 2, proof of concept, randomized, open-label, two-arm, parallel group, multi-center study to assess the efficacy and safety of FK778 compared with standard care in renal transplant recipients with untreated biopsy-diagnosed BK Nephropathy.

This protocol looks to assess the efficacy and safety of FK778 vs. standard care of CNI, anti-proliferative agent, and steroids in patients diagnosed with BK nephropathy confirmed by renal biopsy.

Role: PI

Total Direct Costs: \$154,000

-Novartis Pharmaceuticals

01/01/06-12/01/09

A 24-month, multi-center, randomized, open-label non-inferiority study of the efficacy and safety comparing two concentration-controlled Certican regimens with reduced Neoral versus Myfortic with standard dose Neoral in de novo renal transplant recipients

This protocol examines the benefit of a newly-developed mTOR inhibitor (Certican) in combination with reduced CNI compared to standard CNI.

Role: PI

Total Direct Costs: \$187,200

-Isotechnika, Inc.

07/01/06-12/31/07

A Phase IIB, randomized, multi-center, open-label, concentration-controlled, safety study of ISA247 and Tacrolimus (Prograf®) in de novo renal transplant patients

This protocol examines the benefit of a new CNI (ISA247) with limited renal toxicity compared to standard CNI in newly transplanted renal recipients.

Role : PI

Total Direct Costs: \$150,125

-Novartis Pharmaceuticals

08/01/06-02/02/09

A six-month, prospective, multi-center, open label, parallel, randomized study of the safety, tolerability and efficacy of Myfortic (ERL080) with Simulect, Corticosteroids, and two different levels of Tacrolimus in de novo renal transplant recipients.

This protocol evaluates the safety and efficacy of a newly developed mycophenolic acid product (Myfortic) in combination with CNI compared to standard Cellcept.

Role: PI

Total Direct Costs: \$92,611

Clinical Trial Support (Continued):

-Novartis Pharmaceuticals

01/31/07-08/01/08

A 4-week, multicenter, double-blind, randomized, parallel group study to compare the gastrointestinal and tolerability of Myfortic and MMF (CellCept) when administered in combination with calcineurin inhibitors in renal transplant recipients experiencing gastrointestinal intolerance.

This protocol seeks to demonstrate improved tolerability of Myfortic compared to Cellcept in combination with CNI for those renal transplant recipients experiencing GI toxicity secondary to MPA therapy.

Role: PI

Total Direct Costs: \$36,913

-Pfizer, Inc.

11/01/08-07/31/10

A Phase 2 randomized, multicenter, active comparator-controlled trial to evaluate the safety and efficacy of coadministration of CP-690,550 and Mycophenolate Mofetil/Mycophenolate Sodium in de novo kidney allograft recipients (A3921030)

This protocol evaluates the safety and efficacy of a newly developed JAK-3 inhibitor (CP-690,550) compared to CNI with MPA in renal transplant recipients.

Role: PI

Total Direct Costs: \$255,124

-Astellas Pharmaceuticals

04/01/09-3/30/2011

A Phase 2, Randomized, Open-Label, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Alefacept in de novo Kidney Transplant Recipients

This protocol evaluates the safety and efficacy of anti-CD2 (Alefacept) vs. CNI in newly transplanted renal recipients.

Role: PI

Total Direct Costs: \$226,210

-Alavita Inc.

03/01/09-03/01/10

A Phase 2, Two-Part Study of the Safety and Tolerability of Diannexin in Kidney Transplant Recipients

This protocol evaluates the impact of a novel phosphodiesterase inhibitor (Diannexin) on the development and the duration of delayed graft function in newly transplanted renal recipients.

Role:PI

Total Direct Costs: \$249,134

Clinical Trial Support (Continued):

-LifeCell

08/01/09-05/01/10

Incisional hernia repair in multiple morbid patients: A multicenter, prospective, randomized, controlled, single blinded study of Strattice™ reconstructive tissue matrix vs Proceed

This protocol seeks to compare the safety and efficacy of two products (Strattice – bioprosthesis v. Proceed – artificially produced) utilized in complex hernia repair in multiply morbid patients such as transplant recipients.

Role: PI

Total Direct Costs: \$125,990

-Quark Pharmaceuticals, Inc.

11/01/10-5/31/2013

Controlled, Randomized, Prospective, Double-Blind, Multicenter, Phase I/II, Dose-Escalation Study of the Safety, PK, and Clinical Activity of I5NP for Prophylaxis of Delayed Graft Function in Patients Undergoing Deceased Donor Kidney Transplantation

This protocol evaluates the effect of a small interfering ribonucleic acid (siRNA or I5NP) on the development and duration of delayed graft function (DGF) in newly transplanted kidney recipients.

Role: PI

Total Direct Costs: \$141,765

-Novartis Pharmaceuticals

05/01/10 – 3/13/2012

A 12 month, multi-center, randomized, open-label noninferiority study comparing the safety and efficacy of concentration-controlled Everolimus with low dose tacrolimus to CellCept® (mycophenolate mofetil) with standard dose tacrolimus in de novo renal transplant recipients.

This protocol examines the efficacy and safety of mTOR inhibition (Everolimus) compared to CNI in evaluating the 12 month kidney function of newly transplanted renal allograft recipients.

Role: PI

Total Direct Costs: \$296,320

-Angion Pharmaceuticals

6/28/2011 - present

Multicenter Pilot Study of BB3 to Improve Renal Function in Patients with Signs and Symptoms of Significant Renal Injury after Kidney Transplantation and at Risk for Dialysis

This protocol evaluates the use of a small molecule mimetic of hepatocyte growth factor/scatter factor (HGF/SF or BB3) whose activity is expected to preserve tissue viability and attenuate dysfunction in the setting of organ injury on the development of delayed graft function in kidney transplant recipients.

Role: PI

Total Direct Costs: \$248,013

Clinical Trial Support (Continued):

-Immune Tolerance Network (ITN) 2/ 19/2011 – 6/60/2012
Immunosuppression with Antithymocyte Globulin, Rituximab, Tacrolimus, and Sirolimus, Followed by Withdrawal of Tacrolimus and Sirolimus, in Living-donor Renal Transplant Recipients.

This protocol sponsored by the ITN seeks to demonstrate immune tolerance of living donor kidney transplant recipients by progressively weaning patients off immunosuppressive medications over a 3 year period.

Role:PI

Total Direct Costs:

-Alberta Transplant Applied Genomics Centre 6/22/2011 – 6/30/2012
The International Collaborative Microarray (INTERCOM) Study

This project aims to develop a new diagnostic system that combines the molecular and histopathological features of kidney transplant biopsies, plus clinical and laboratory parameters, to create the first Integrated Diagnostic System to better direct the care of kidney transplant recipients.

PI: Jonathan Bromberg, MD

Role: Co-investigator

Total Direct Costs: \$56,144

-American Society of Transplant Surgeons 6/29/2011 – 6/30/2012
Changes in the human microbiota induced by post-transplant medication

This protocol is a highly innovative human microbiome research project with the goal to determine the functional setup of the healthy human microbiota, in order to develop prebiotic, probiotic or antibiotic options that could be used as a concomitant treatment in addition to the standard immunosuppressive and antimicrobial therapy.

PI: Jonathan Bromberg, MD

Role: Co-investigator

Total Direct Costs: \$100,000

-Alexion Pharmaceuticals 10/11/2012 - present
A randomized, open-label, multi-center trial to determine safety and efficacy of Eculizumab in the prevention of antibody mediated rejection (AMR) in living donor kidney transplant recipients requiring desensitization.

This protocol was designed to determine the efficacy of employing a complement-inhibitor in the prevention of AMR in living donor pairs who have been found to have a positive crossmatch and in need of pre-transplant desensitization.

Role: PI

Total Direct Costs: \$129,366

Clinical Trial Support (Continued):

-Genentech, Inc

3/3/2013 – present

A phase II randomized, double-blind, placebo-controlled trial of MCMV5322A/MCMV3068A for the prevention of cytomegalovirus disease in high-risk kidney allograft recipients

The purpose of this trial is to evaluate the safety of multiple doses of MCMV5322A/MCMV3068A given intravenously (IV) to CMV seronegative recipients of a renal transplant from a CMV seropositive donor in the absence of standard prophylaxis.

Role: PI

Total Direct Costs: \$355,268.80

-KCI USA, Inc.

7/15/2013- present

The use of Provena incision management system on closed recipient site incisions in renal transplant subjects

The goal of this investigator-initiated trial is to demonstrate decreased wound complications (ie. infections, seromas, dehiscence) with the use of a negative-pressure wound closure device compared to standard of care.

Role: PI

Total Direct Costs: \$653,751.50

-Opsona Therapeutics

7/15/2013 –present

A three-part, multi-center, randomized, double-blind, placebo-controlled, parallel-group, sequential adaptive phase 2 study to evaluate the safety, tolerability, and efficacy of OPN305, a humanized, monoclonal antibody that blocks toll-like receptor 2, in renal transplant recipients at high risk of delayed graft function.

The purpose of this trial is to assess the efficacy of an antibody formulated against the TLL-2 receptor which has been demonstrated to be significantly upregulated during ischemia reperfusion injury in kidney transplant recipients of an organ from an expanded criteria donor.

Role: PI

Total Direct Costs: \$218,220.80

Publications (Peer –Reviewed)

1. Cooper M, Dembny KD, Lindholm P, Lai C, Moore G, Johnson CP, Adams MB, Pieper GM, Roza AM: Effect of Nitric Oxide Scavenging and Inhibition of NF- κ B Activity on Cardiac Allograft Survival. *Surg Forum XLVII*: 500-503, 1997.
2. Cooper M, Lindholm P, Pieper GM, Seibel R, Moore G, Nakanishi A, Dembny KD, Komorowski RJ, Johnson CP, Adams MB, Roza AM: Myocardial Nuclear Factor KappaB (NF- κ B) Activity and Nitric Oxide Production in Rejecting Cardiac Allografts. *Transplantation* 66(7): 838-44, 1998.
3. Pieper GM, Cooper M, Nakashini A, Dembny KD, Lindholm P, Lai C, Moore G, Johnson CP, Adams MB, Roza AM: Nuclear Factor KappaB (NF- κ B), Nitrosomyoglobin Signals and Increased Nitric Oxide in Cardiac Transplantation. *Nit Oxide: Bio and Chem* 2: 296, 1998.
4. Pieper GM, Cooper M, Johnson CP, Adams MB, Felix C, Roza AM: Reduction of Myocardial Nitrosyl Complex Formation by a Nitric Oxide Scavenger Prolong Cardiac Allograft Survival. *J Cardiovasc Pharmacol* 35: 114-121, 2000.
5. Roza AM, Cooper M, Pieper GM, Hilton G, Dembny KD, Lai C, Lindholm P, Komorowski RJ, Felix C, Johnson CP, Adams MB: Nox 100, A Nitric Oxide Scavenger, Enhances Cardiac Allograft Survival and Promotes Long-Term Graft Acceptance. *Transplantation* 69(2): 227-231, 2000.
6. Arepally A, Dagli M, Hofmann LV, Kim HS, Cooper M, Klein A: Treatment of Splenic Artery Aneurysm with the Use of a Stent-Graft. *J Interven Radiol* 13(6): 227-31, 2002.
7. Molmenti EP, Pinto PA, Montgomery RA, Su LM, Kraus E, Cooper M, Sonnenday CJ, Klein AS, Kavoussi LR, Ratner LE: Concomitant Surgery with Laparoscopic Donor Nephrectomy. *Am J Transplant* 3(2): 219-23, 2003.
8. Sonnenday CJ, Cooper M, Kraus E, Gage F, Handley C, Montgomery RA: The Hazards of Acceptance of Cadaveric Renal Allografts on Pulsatile Perfusion Parameters Alone. *Transplantation* 75(12): 2029-33, 2003.
9. Montgomery RA, Cooper M, Kraus E, Rabb H, Samaniego M, Simpkins CE, Sonnenday CJ, Ugarte RM, Warren DS, Zachary AA: Renal Transplantation at the Johns Hopkins Comprehensive Transplant Center. *Clin Transpl* 199-213, 2003.
10. Sonnenday CJ, Warren DS, Cooper M, Samaniego M, Haas M, King KE, Shirey RS, Simpkins CE, Montgomery RA: Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. *Am J Transplant* 4(4): 1315-1322, 2004.

Publications (Continued):

11. Warren DS, Zachary AA, Sonnenday CJ, King KE, Cooper M, Ratner LE, Shirey RS, Haas M, Leffell MS, Montgomery RA: Successful Renal Transplantation Across ABO Incompatible and Positive Crossmatch Barriers. *Am J Transplant* 4(4): 561-568, 2004.
12. Warren DS, Simpkins CE, Cooper M, Montgomery RA: Modulating Alloimmune Responses with Plasmapheresis and IVIG. *Curr Drug Targets Cardiovasc Haematol Disord* 5(3): 215-222, 2005.
13. Segev DL, Simpkins CE, Warren DS, Cooper M, Maley WR, Melancon JK, Kozlowski T, Montgomery RA: ABO Incompatible High Titer Renal Transplantation without Splenectomy or Anti-CD20 Treatment. *Am J Transplant* 5(10): 2570-2575, 2005.
14. Montgomery RA, Zachary AA, Ratner LE, Segev DL, Hiller JM, Houp J, Cooper M, Kavoussi L, Jarrett T, Burdick J, Maley WR, Melancon JK, Kozlowski T, Simpkins CE, Phillips M, Desai A, Collins V, Reeb B, Kraus E, Rabb H, Warren DS: Clinical Results from Transplanting Incompatible Live Kidney Donor/Recipient Pairs Using Kidney Paired Donation. *JAMA* 294(4): 1655-63, 2005.
15. Walton-Moss B, Boulware E, Cooper M, Taylor L, Dane K, Nolan MT: Prospective Pilot Study of Living Kidney Donor Decision Making and Outcomes. *Clinical Transplantation* 21: 86-93, 2007.
16. Wali RK, Mohanlal V, Ramos E, Blahut S, Drachenberg C, Papadimitriou J, Dinitz M, Joshi A, Philosophe B, Foster C, Cangro C, Nogueira J, Cooper M, Bartlett ST, Weir MR: Early Withdrawal of Calcineurin Inhibitors and Rescue Immunosuppression with Sirolimus-Based Therapy in Renal Transplant Recipients with Moderate to Severe Renal Dysfunction. *Am J Transplant* 7(6) 1572-1583, 2007.
17. Hitti W, Drachenberg C, Cooper M, Schweitzer E, Cangro C, Klassen D, Haririan A: Xanthogranulomatous Pyelonephritis In a Renal Allograft Associated With Xanthogranulomatous Diverticulitis: A Report of the First Case and Review of the Literature. *Nephrol Dial Transplant* 22(11) 3344-3347, 2007.
18. Jacobs SC, Nogueira JM, Phelan MW, Bartlett ST, Cooper M. Transplant Recipient Renal Function is Donor Renal Mass- and Recipient Gender-Dependent. *Transpl Int* 12, 2007.
19. Bolin P, Tanriover B, Zibari GB, Lynn ML, Pirsch JD, Chan L, Cooper M, Langone AJ, Tomlanovich SJ: Improvement in 3-Month Patient-Reported Gastrointestinal Symptoms After Conversion From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Renal Transplant Patients. *Transplantation* 84(11) 1443-1451, 2007.

Publications (Continued):

20. Chan L, Greenstein S, Hardy MA, Hartmann E, Bunnapradist S, Cibrik D, Shaw LM, Munir L, Ulbricht B, Cooper M. Multicenter, Randomized Use of Everolimus With Tacrolimus After Renal Transplantation Demonstrates Its Effectiveness. *Transplantation* 85(6) 821-826, 2008.
21. Sener A and Cooper M. Live Donor Nephrectomy for Kidney Transplantation. *Nat Clin Prac Uro* 5(4) 203-210, 2008.
22. Nogueira J, Jacobs S, Haririan A, Phelan M, Weir M, Selinger S, Hurley H, Cooper M. A single center comparison of long-term outcomes of renal allografts procured laparoscopically versus historic controls procured by the open approach. *Transpl Int* (21) 908-914, 2008.
23. Munivenkatappa R, Papadimitriou J, Drachenberg C, Schweitzer E, Haririan A, Rasetto F, Cooper M, Campos L, Barth R, Bartlett S, Philosophe B. The Maryland Aggregate Pathology Index (MAPI). A Deceased Donor Kidney Biopsy Scoring System for Predicting Graft Failure. *Am J Trans* 8(11) 2316-2324, 2008.
24. Kramer A, Sauseville J, Haririan A, Bartlett S, Cooper M, Phelan M. Simultaneous Bilateral Native Nephrectomy and Living Donor Renal Transplantation is Successful for Polycystic Kidney Disease: The University of Maryland Experience. *J Uro* 181(2) 724-728, 2008.
25. Nogueira J, Haririan A, Jacobs S, Weir M, Hurley H, Al-Qudah H, Phelan M, Drachenberg C, Bartlett S, Cooper M. The Detrimental Effect of Poor Early Graft Function After Laparoscopic Live Donor Nephrectomy on Graft Outcomes. *Am J Trans* 9(2) 337-347, 2009.
26. Cooper M, Deering K, Arcona S, Wiland A. Gastrointestinal Tolerability of Enteric-Coated Mycophenolate Sodium in Renal Transplant Recipients: A Literature Review. *Clin Trans* (in press).
27. Scalea J, Butler C, Manivenkatappa R, Barth R, Schweitzer E, Philosophe B, Bartlett S, Cooper M. Pancreas Transplant Alone (PTA) as an Independent Risk Factor for the Development of Renal Failure. *Transplantation* 86(12) 1789-1794, 2009.
28. Haririan A, Nogueira J, Kukuruga D, Schweitzer E, Hess J, Gurk-Turner C, Jacobs S, Drachenberg C, Bartlett S, Cooper M. Positive cross-match living donor kidney transplantation: longer-term outcomes. *Am J Trans* 9(3) 536-542, 2009.
29. Sener A, Schweitzer E, Munivenkatappa R, Cooper M, Bartlett S, Philosophe B, Barth R. Deceased Donor Renal Transplantation in the Geriatric Population Demonstrates Equal Graft Survival Compared With Younger Recipients. *Transplantation* 87(10) 1549-1555, 2009.
30. Davis C, Cooper M. Long-term Consequences of Kidney Donation. *NEJM* 360(22) 2370, 2009.

Publications (Continued):

31. Montgomery R, Locke J, King K, Segev D, Warren D, Kraus E, Cooper M, Simpkins C, Singer A, Stewart Z, Melancon J, Ratner L, Zachary A, Haas M. ABO Incompatible Renal Transplantation: A Paradigm for Broad Implementation. *Transplantation* 87(8), 1246-1255, 2009.
32. Cooper M, Deering K, Slakey D, Harshaw Q, Arcona S, McCann E, Rasetto F, Florman S. Comparing outcomes associated with dose manipulations of enteric-coated Mycophenolate sodium versus Mycophenolate Mofetil in renal transplant recipients. *Transplantation* 88(4), 514-520, 2009.
33. Haririan A, Kiagkitiwan B, Kukuruga D, Cooper M, Hurley H, Drachenberg C, Klassen D. The impact of C4d pattern and donor-specific antibody on graft survival in recipients requiring indication renal allograft biopsy. *Am J Trans* 9(12), 2758-2767, 2009.
34. Nogueira J, Weir M, Jacobs S, Haririan A, Breault D, Klassan D, Evans D, Bartlett S, Cooper M. A Study of Renal Outcomes in African American Living Kidney Donors. *Transplantation* 88(12), 1371-1376, 2009.
35. Haririan A, Zandi-Nejad K, Aiyer R, Hurley H, Cooper M, Klassen D, Weir M. The independent association between serum uric acid and graft outcomes after kidney transplantation. *Transplantation* 89(5), 573-579, 2010.
36. Chan L, Hartmann E, Cibrik D, Cooper M, Shaw L. Optimal Everolimus Concentration is Associated with Risk Reduction in De Novo Renal Transplant Recipients. *Trasnplantation* 90(1), 31-37, 2010.
37. Nogueira J, Haririan A, Jacobs S, Cooper M, Weir M. Cigarette Smoking, Kidney Function, and Mortality after Live Donor Kidney Transplantation. *AJKD* 55(5), 907-915, 2010.
38. Irish W, Arcona S, Giffard R, Ballie M, Cooper M. Enteric-Coated Mycophenolate Sodium (EC-MPS) versus Mycophenolate Mofetil (MMF) Maintenance Immunosuppression: Outcomes Analysis of the UNOS/OPTN Database. *Transplantation* 90(1), 23-30, 2010.
39. Sener A, Cooper M, Bartlett S. Is There a Role for Pancreas Transplantation in Type-2 Diabetes Mellitus. *Transplantation* 90(2), 121-123, 2010.
40. Bartlett S, Schweitzer E, Cooper M. Prediction Model for Delayed Kidney Transplant Function: No Need for New Regulation. *Am J Transplant* 10(10), 2191-2192, 2010.
41. Davis C, Cooper M. The Status of U.S. Living Kidney Donors. *Clin J Am Soc Nephrol* 5(10), 1873-1880, 2010.
42. Brewer M, Rada E, Milburn M, Goldberg N, Singh D, Cooper M, Silverman R. Human Acellular Dermal Matrix for Ventral Hernia Repairs Reduced Morbidity in Transplant Patients. *Hernia* 15(2), 141-145, 2010.

Publications (Continued):

43. Nogueira J, Weir M, Jacob S, Breault D, Klassen D, Evans D, Bartlett S, Cooper M. A Study of Renal Outcomes in Obese Living Kidney Donors. *Transplantation* 90(9), 993-999, 2010.
44. Montgomery R, Segev D, Lonze B, Haas M, King K, Kraus E, Locke J, Warren D, Cooper M, Simpkins C, Dagher N, Singer A, Samaniego-Picota M, Ratner L, Kucirka L, Leffel M, Zachary A. Desensitization of HLA-Incompatible Kidney Recipients Provides a Survival Benefit. *NEJM* 365(4), 318-326, 2011.
40. Langone A, Chan L, Bolin P, Cooper M. Enteric-Coated Mycophenolate Sodium Versus Mycophenolate Mofetil in Renal Transplant Recipients Experiencing Gastrointestinal Intolerance: A Multi-Center, Double-Blind, Randomized Study. *Transplantation* 91(4),470-478, 2011 .
45. Segev D, Veale JL, Berger JC, Hiller JM, Hanto RL, Leeser DB, Geffner SR, Shenoy S, Bry WI, Katznelson S, Melcher ML, Rees MA, Samara EN, Israni AK, Cooper M, Montgomery RJ, Malinzak L, Whiting J, Baran D, Tchervenkov JI, Roberts JP, Rogers J, Axelrod DA, Simpkins CE, Montgomery RA. Transporting Live Donor Kidneys for Kidney Paired Donation: Initial National Results. *Am J Transplant* 11(2), 356-360, 2011.
46. Manitpisitkul W, Wilson N, Philosophe B, Cooper M, Drachenberg C, Kukuruga D, Nogueira J, Haririan A. Rescue Therapy for Acute Antibody-Mediated Rejection with a Proteasome Inhibitor after Kidney Transplantation. *Clin Trans* 421-428, 2010.
47. Haririan A, Metireddy M, Cangro C, Noguiera J, Rasetto F, Cooper M, Klassen D, Weir M. Association of Serum Uric Acid with Graft survival After Kidney Transplantation; a Time-varying Analysis. *Am J Trans* 11(9), 1943-50, 2011
48. Leichtman A, Abecassis M, Barr M, Charlton M, Cohen D, Confer D, Cooper M, Danovitch G, Davis C, Delmonico F, Dew MA, Garvey C, Gaston R, Gill J, Gillespie B, Ibrahim H, Jacobs C, Kahn J, Kasiske B, Kim J, Lentine K, Manyalich M, Medina-Pestana J, Merion R, Moxey-Mims M, Odum J, Opelz G, Orłowski J, Rizvi A, Roberts J, Segev D, Sledge T, Steiner R, Taler S, Textor S, Thiel G, Waterman A, Williams E, Wolfe R, Wynn J, Matas AJ. Living kidney donor follow-up: state-of-the-art and future directions, conference summary and recommendations. *Am J Transplant* 11(12), 2561-2568, 2011.
49. Fayek S, Keenan J, Haririan A, Cooper M, Barth R, Schweitzer E, Bromberg J, Bartlett S, Philosophe B. Ureteral Stents are Associated with a Reduced Risk of Ureteral Complications After Kidney Transplant: A Large Single Center Experience. *Transplantation* 93(3), 304-8, 2012.
50. Chisholm-Burns M, Pinsky B, Arcona S, Cooper M. Factors Related to Immunosuppressant Medication Adherence in Renal Transplant Recipients. *Clinical Transplantation* 26(5), 706-713, 2012.

Publications (Continued):

51. Cooper M, Salvadori M, Budde K, Oppenheimer F, Sollinger H, Zeier, M. Enteric-coated Mycophenolate Sodium Immunosuppression in Renal Transplant Patients: Efficacy and Dosing. *Transplantation Reviews* 2012 Oct;26(4):233-40. doi: 10.1016/j.trre.2012.02.001. [Epub ahead of print]
52. Smith D, Chudgar A, Daly B, Cooper M. Evaluation of Potential Renal Transplant Recipients with Computed Tomography Angiography. *Arch Surg* 2012 Dec 1;147(12):1114-22. doi: 10.1001/archsurg.2012.1466 [Epub ahead of print].
53. Waterman A, Dew MA, Davis C, McCabe M, Wainright J, Forland C, Bolton L, Cooper M. Living Donor Follow-up Attitudes and Practices in US Kidney and Liver Donor Programs. *Transplantation* 95(6), 883-888, 2013
54. Phelan M, Kramer A, Jacobs S, Cooper M. Living Donor Relationship in Caucasian and African-American Populations and Implications for Targeted Donor Education Programs. *Clin Transplant* 2012 Jul 9. doi: 10.1111/j.1399-0012.2012.01685.x. [Epub ahead of print].
55. Phelan M, Kramer A, Nogueira J, Cooper M. Recipient Outcomes of Dual and Multiple Renal Arteries Following 1000 Consecutive Laparoscopic Donor Nephrectomies at a Single Institution. *Clin Transplant* 2013 Jan 10. doi: 10.1111/ctr.12062. [Epub ahead of print].
56. Gurk-Turner C, Manitpiskitul W, Cooper M. A Comprehensive Review of Everolimus Clinical Reports - A New mTOR Inhibitor. *Transplantation* 2012 Oct 15;94(7):659-68. doi: 10.1097/TP.0b013e31825b411c. [Epub ahead of print].
57. Wiseman A, Kim Y, Geissler F, McCague K, Cooper M. The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes. *Am J Transplant* 3 DEC 2012 | DOI: 10.1111/j.1600-6143.2012.04334.x [Epub ahead of print]
58. Philosophe B, Cooper M, Munivenkatappa R. Validation of the Maryland Aggregate Pathology Index (MAPI), a Pre-implantation Scoring System that Predicts Graft Outcome. *J Am Soc Neph* (submitted).
59. Cooper M, Wiseman AC, Zabari G, McCague K, Kim Y, Geissler F, Nashan B. Wound events in Kidney Transplant Patients Receiving de novo Everolimus: A Pooled Analysis of Three Randomized Controlled Trials. *Clinical Transplantation* (accepted for publication).
60. Scalea J, Menaker J, Meeks AK, Kramer ME, Kufera JA, Auman KM, Cooper M, Bartlett S, Scalea TM. Trauma Patients with a Previous Organ Transplant: Outcomes are Better than Expected- A Retrospective Analysis. *J Trauma Acute Care Surg*. (accepted for publication).

Publications (Continued):

61. Scalea J, Cooper M. A Possible Role for Statin Therapy in Solitary Pancreas Transplantation? *Trans Proc* (accepted for publication).
62. Chen Y, Verbessey J, Cooper M. Optical Coherence Tomography of the Living Human Kidney. *J Innov Opt Health Sci* (accepted for publication).
63. Sosin M, Lumeh, W, Cooper M. Torsion of the Retroperitoneal Kidney: Uncommon or Underreported? A Case Report and Review of the Literature. *Case Reports Trans* (accepted for publication).
64. Orandi B, Massie A, Zachary A, Ratner L, Cooper M Montgomery R, Segev D. Quantifying the Risk of Incompatible Kidney Transplantation: A Multi-Center Study *Am J Transplant* (accepted for publication).
65. Scalea J, Barth R, Philippe B, Cooper M, LaMattina J. Shorter waitlist time for HCV+ renal allografts improves long-term graft survival without associated progression of clinical liver disease. *Transplantation* (submitted).

Abstracts:

1. Cooper M, Dembny KD, Lindholm P, Lai C, Moore G, Johnson CP, Adams MB, Pieper GM, Roza AM: Longterm Allograft survival with Nitric Oxide Scavenging. The Transplantation Society XVII World Congress. Montreal, July 1997.
2. Pieper GM, Cooper M, Nakashini A, Dembny KD, Lindholm P, Lai C, Moore G, Johnson CP, Adams MB, Roza AM: Nuclear Factor KappaB (NF- κ B), Nitrosomyoglobin Signals and Increased Nitric Oxide in Cardiac Transplantation. XIIIth IUPHAR World Congress of Pharmacology. Milan, October 1998.
3. Ratner LE, King K, Tan HP, Zachary AA, Samaniego MD, Kraus ES, Cooper M, Montgomery, R: Plasmaphoresis and Intravenous immune globulin (Ig) for the Treatment of Antibody-mediated rejection in renal transplantation. Chicago, AST/ASTS, May 14, 2001.
4. Ratner LE, Sinkov V, Montgomery RA, Fox-Talbot K, Tan HP, Cooper M, Kavoussi LR: Laparoscopic live donor nephrectomy: Global status at the millennium. Chicago, AST/ASTS, May 14, 2001.
5. Devera J, Cooper M, Paredes M, Burdick J, Samaniego M, Molmenti E: Comparison of Cytomegalovirus Prophylaxis Regimens in Kidney and Pancreas Transplantation. Washington, DC, AST/ASTS, April 29, 2001.
6. Devera J, Cooper M, Paredes M, Thulavath P, Rai R, Arrazola L, Klein A, Molmenti E: Cytomegalovirus Prophylaxis in Liver Transplant Recipients. Chicago, ILTS, June 15, 2002.

Abstracts (Continued):

7. Molmenti EP, Pinto P, Montgomery RA, Su LM, Kraus ES, Cooper M, Karp S, Falta E, Sonnenday CJ, Klein AS, Kavoussi LR, Ratner LE: Concomitant Surgery with Laparoscopic Live Donor Nephrectomy. Dana Point, CA, International College of Surgeons, June 2002.
8. Devera J, Paredes M, Holecheck MJ, Lees L, Eustace J, Montgomery RA, Kraus ES, Samaniego M, Burdick JB, Cooper M, Scheel P, Klein AS, Molmenti EP: Comparison of Cytomegalovirus Prophylaxis Regimens in Kidney and Pancreas Transplantation. Miami, FL, XIX International Congress, August 2002.
9. Cooper M, Kraus ES, Zachary AA, Leffell MS, Racussen LC, Haas M, Burdick JF, Montgomery RA, Eustace JA, Reeb B, Ratner LE, Rabb H, Molmenti EP: Increased Incidence of Rejection According to HLA Composition in Extended Criteria Cadaveric Renal Allografts. Miami, FL, XIX International Congress, August 2002.
10. Molmenti E, Montgomery RA, Sonnenday CJ, Pinto PA, Samaniego M, Kraus ES, Cooper M, Falta E, Karp S, Su L, Rabb H, Hsu T, Klein AS, Kavoussi LR, Ratner LE: Laparoscopic Live Donor Nephrectomy in the Elderly. Miami, FL, XIX International Congress, August 2002.
11. Cooper M, Zachary A, Graziani J, Montgomery R, Leffell, M: Anti-HLA Antibody Emergence after Nonspecific Activation of Immune System, Washington, DC, ATC, June 2, 2003.
12. Sonnenday C, Warren D, Zachary A, King K, Cooper M, Haas M, Montgomery R: Renal Transplantation in Patients Who Have Both A Positive Crossmatch and ABO-Incompatibility with Their Live Donor. Washington, DC, ATC, June 1, 2003.
13. Cooper M, Zachary A, Graziani JA, Montgomery R, Laffell M: Non-specific activation of the immune system can provoke anti-HLA antibodies. Miami, ASHI, November 1, 2003.
14. Cooper M, Hiller J, Rickard J, Rabb H, Zachary A, Graziani J, Montgomery R: Conventional and Unconventional Paired Kidney Exchanges. Boston, MA, ATC, May 16, 2004.
15. Montgomery R, Simpkins C, Zachary A, Lees L, Warren D, Cooper M, Samaniego M: Anti – CD20 Rescue Therapy for Kidneys Undergoing Antibody-Mediated Rejection. Boston, MA, ATC, May 14, 2004.
16. Ugarte R, Racusen L, Haas M, Leffell, M, Zachary A, Samaniego M, Molmenti E, Cooper M, Montgomery R, Rabb H: Thymoglobulin Versus No induction in Adult Primary Deceased-Donor Renal Transplant Recipients on Maintenance Tacrolimus, Cellcept, and Prednisone – A Single Center Longitudinal Study. Boston, MA, ATC, May 15, 2004.
17. Simpkins C, Warren D, Sonnenday C, Cooper M, King K, Haas M, Montgomery R: Accommodation of ABO- Incompatible Renal Allografts is Associated with Persistent C₄d Staining. Boston, MA, ATC, May 19, 2004.

Abstracts (Continued):

18. Simpkins C, Zachary A, Cooper M, Warren D, Ratner L, Montgomery R: Improved Results with Selective Use of Splenectomy and Anti-CD20 For Positive Crossmatch Transplants. Boston, MA, ATC, May 18, 2004.
19. Ugarte RM, Eustace JA, Rabb H, Samaniego M, Cooper M, Montgomery RA, Molmenti E, Kraus E: The effect of Thymoglobulin induction on acute rejection, graft survival, and renal function in high-risk primary deceased-donor renal transplants: A single center longitudinal study. St. Louis, MO, ASN, Nov. 1, 2004.
20. Ugarte RM, Eustace JA, Rabb H, Samaniego M, Cooper M, Montgomery RA, Molmenti E, Kraus E: Reduced acute rejection rate with Thymoglobulin compared to Interleukin-2 (IL-2R) blocker induction therapy in a high risk deceased-donor population at a single center. St. Louis, MO, ASN, Nov. 1, 2004.
21. Zachary A, Montgomery RA, Samaniego M, Cooper M, Vega R, Lefell M: Desensitization protocols: Antibodies that won't go away. San Antonio, ASHI, October 2, 2004.
22. Segev DL, Warren DS, Simpkins CI, Zachary A, Cooper M, Montgomery RA: Controlled Hyperacute Rejection. San Diego, 3rd International Congress on Immunosuppression, December 10, 2004.
23. Ugarte R, Mehta T, Hawxby A, Karp S, Montgomery R, Cooper M, Rabb H, Racusen L, Haas M, Zachary A, Kraus E: Donor Acute Tubular Necrosis Predicts Early Acute Rejection in Deceased-Donor Renal Transplants: A Single-Center Longitudinal Study. Seattle, WA, ATC, May 24, 2005.
24. Warren D, Simpkins C, King K, Zachary A, Sonnenday C, Cooper M, Melancon J, Segev D, Kozlowski T, Rabb H, Shirey S, Montgomery R: Excellent Results Achieved For ABOI Renal Allografts With or Without Splenectomy. Seattle, WA, ATC, May 22, 2005.
25. Montgomery R, Cooper M, Zachary A, Lefell M, Hiller J, Warren D: Excellent Outcomes Achieved With Paired Kidney Exchange. Seattle, WA, ATC, May 22, 2005.
26. Nogueira J, Cooper M, Al-Qudah H, Phalen M, Weir M, Philosophe B, Jacobs S, Bartlett S: Recipient Renal Outcomes of the First 1000 Laparoscopic Live Donor Nephrectomies at a Single Institution. Boston, MA, WTC, July 24, 2006.
27. Al-Qudah H, Philosophe B, Hurley H, Schweitzer E, Campos L, Cooper M, Bartlett S: Variables Affecting Outcomes of Dual Kidney Transplants. Boston, MA, WTC, July 25, 2006.
28. Al-Qudah H, Philosophe B, Hurley H, Schweitzer E, Cooper M, Campos L, Bartlett S: Long Term Outcomes of Dual Kidney Transplantation. Boston, MA, WTC, July 25, 2006.

Abstracts (Continued):

29. Cooper M, Al-Qudah H, Jacobs S, Phelan M, Nogueira J, Philosophe B, Bartlett S: Laparoscopic Donor Nephrectomy for Transplantation: 10 Years and 1000 Consecutive Cases. Boston, MA, WTC, July 25, 2006.
30. Chan L, Cooper M, Leventhal J, Munir L: Excellent Renal Function at 6 Months in De Novo Kidney Transplant Recipients Treated with Everolimus, Basiliximab and Reduced Dose Tacrolimus Exposure. Boston, MA, WTC, July 25, 2006.
31. Wali, R, Cooper M, Foster C, Philosophe B, Al-Hitti W, Dinits M, Nogueira J, Bartlett S, Ramos E, Drachenberg C, Papadimitriou J, Amber R, Cho D, Weir M: Early Tacrolimus Withdrawal and Rescue Therapy with Sirolimus in High-Risk Renal Transplant Recipients with Moderate to Severe Chronic Allograft Nephropathy. Boston, MA, WTC, July 25, 2006.
32. Philosophe B, Campos L, Cooper M, Schweitzer E, Al-Qudah H, Bartlett S: Long Term Outcomes of Hepatitis C Positive Kidney Transplant Recipients of HCV+ and HCV- Donors. Boston, MA, WTC, July 25, 2006.
33. Cooper M, Philosophe B, Fink J, Schweitzer E, Campos L, Al-Qudah H, Bartlett S: Successful Educational Programs and Pre-Emptive Kidney Transplantation Yields Encouraging Results. Boston, MA, WTC, July 25, 2006.
34. Campos L, Al-Qudah H, Philosophe B, Cooper M, Schweitzer E, Bartlett S: Pediatric En-Block Renal Allografts: A Single Institution Experience. Boston, MA, WTC, July 25, 2006.
35. Cooper M, Jacobs S, Phelan M, Nogueira J, Al-Qudah H, Philosophe B, Bartlett S: Critical Role of Nephron Dosing: Gender Difference in Outcome for Recipients of Female Live Donor Kidney Transplants. Boston, MA, WTC, July 26, 2006.
36. Cooper M, Jacobs S, Phelan M, Nogueira J, Al-Qudah H, Philosophe B, Bartlett S: Outcomes Following Vascular Reconstruction for 1000 Consecutive Laparoscopic Donor Nephrectomies. Boston, MA, WTC, July 27, 2006.
37. Munivenkatappa R, Schweitzer E, Cooper M, Bartlett S, Campos L, Papadimitriou J, Drachenberg C, Philosophe B: Computerized Morphometric Studies of Pre-Implantation Donor Wedge Biopsies: Significance of Arterial Abnormalities. Boston, MA, WTC, July 27, 2006.
38. Nogueira J, Jacobs S, Cooper M, Klassen D, Al-Qudah H, Weir M: A Cross-Sectional Study of African American Kidney Donors to Assess Risk for Adverse Renal Outcomes. San Diego, CA, ASN, Nov. 18, 2006.
39. Nogueira J, Jacobs S, Cooper M, Klassen D, Al-Qudah H, Weir M: A Cross-Sectional Study of Obese Kidney Donors to Assess Risk for Adverse Renal Outcomes. San Diego, CA, ASN, Nov. 18, 2006.

Abstracts (Continued):

40. Cooper M, Phelan M, Jacobs S, Nogueira J, Haririan A, Schweitzer E, Campos L, Philosophe B, Bartlett S: Living Kidney Donor Relationship in Caucasian and African-American Populations and Implications For Targeted Donor Education Programs. Phoenix, AZ, SUS/AAS, Feb 9, 2007.
41. Barth R, Schweitzer E, Cooper M, Campos L, Bartlett S, Philosophe B: Simultaneous Pancreas Living Donor Kidney Transplantation (SPLK) Provides Superior 5-Year Results as Compared to Simultaneous Pancreas Kidney Transplantation (SPK). San Diego, CA, ATC, May 7, 2007.
42. Haririan A, Zanki-Nejad K, Nogueira J, Hurley H, Owens E, Chandraker A, Cooper M, Klassen D, Jacobs S: The Role of Uric Acid as a Risk Factor for Worse Graft Outcomes After Kidney Transplantation. San Diego, CA, ATC May 6, 2007.
43. Nogueira J, Haririan A, Cooper M, Weir M, Hurley H, Jacobs S: The Effect of Pre-Donation Estimated Glomerular Filtration Rate on Recipient Renal Function after Live Donor Kidney Transplantation. San Diego, CA, ATC, May 6, 2007.
44. Cooper M, Miller J, Campos L, Barth R, Philosophe B, Bartlett S: Redefining Expanded in Expanded Criteria Donors and Its Effect on Outcomes Data. San Diego, CA, ATC, May 6, 2007.
45. Philosophe B, Hurley H, Butler K, Schweitzer E, Campos L, Cooper M, Barth R, Bartlett S: Differential Effects of Thymoglobulin Depletion and Basiliximab Induction in Sensitized Patients Undergoing Renal Transplantation. San Diego, CA, ATC, May 8, 2007.
46. Cooper M, Nogueira J, Haririan A, Hurley H, Jacobs S, Schweitzer E, Campos L, Barth R, Philosophe B, Bartlett S: Impact of Induction Agents on Renal Recipient Outcomes of the First 1000 Laparoscopic Donor Nephrectomies at a Single Institution. San Diego, CA, ATC, May 8, 2007.
47. Wali RK, Blahut S, Mohanlal V, Drachenberg C, Philosophe B, Cooper M, Ramos E, Joshi A, Bartlett S, Weir MR: Can We Improve the Outcome of Allograft Survival in Patients with Progressive Graft Dysfunction Due to Chronic Allograft Nephropathy (CAN)? A Preliminary Report. San Diego, CA, ATC, May 8, 2007.
48. Campos L, Scalea J, Schweitzer E, Cooper M, Bartlett S, Philosophe B: Pancreatic Replantation: Single Institution Experience. San Diego, CA, ATC, May 8, 2007.
49. Schroder N, Haririan A, Welsh C, Cooper M: When Family Secrets are Uncovered: Discovery of Misattributed Paternity Information at US Transplant Centers. Chicago, IL, Frontiers of Ethics in Transplantation, April 5, 2008.

Abstracts (Continued):

50. Schroder N, Haririan A, Welsh C, Cooper M: Psychosocial Follow-Up Practices for Living Kidney Donors (LKD) at US Transplant Centers. Toronto, ATC, June 1, 2008.
51. Sener A, Barth R, Cooper M, Campos L, Schweitzer E, Bartlett S, Philosophe B: T-Cell Depletion Does Not Potentiate the Progression of Liver Cirrhosis in HCV+ Renal Transplant Patients. Toronto, ATC, June 1, 2008.
52. Munivenkatappa R, Papadimitriou J, Drachenberg C, Rasetto F, Haririan A, Schweitzer E, Cooper M, Barth R, Campos L, Bartlett S, Philosophe B: Predicting Graft Outcome with a Pre-Transplant Kidney Biopsy Using a Cumulative Pathology Score. Toronto, ATC, June 2, 2008.
53. Kiangkitiwan B, Drachenberg C, Cooper M, Riveros-Angel M, Kukuruga D, Hurley H, Kennedy M, Klassen D, Haririan A: Association between C4d Staining in Kidney Transplant (KT) Biopsies and Donor Specific Antibody (DSA). Toronto, ATC, June 3, 2008.
54. Cooper M, Haririan A, Jacobs S, Phelan M, Philosophe B, Bartlett S, Noqueira J: Predictors of Poor Early Graft Function Following Laparoscopic Donor Nephrectomy (LDN). Toronto, ATC, June 3, 2008.
55. Wali R, Drachenberg C, Hirsch H, Joshi A, Munivenkatappa R, Portocarrero M, Weir M, Cooper M, Bartlett S, Ramos E: Intensive Versus Routine Care Screening for Polyoma Viral Reactivation (Cluster Randomization) and a Road Map for Stepwise Modification of Immunosuppression Therapy (IT). Toronto, ATC, June 3, 2008.
56. Haririan A, Kukuruga D, Cooper M, Schweitzer E, Gurk-Turner C, Jacobs S, Drachenberg C, Bartlett S, Nogueira J: Risk Factors for Poor Graft Outcome after Positive Cross Match (PXM) Living Donor Kidney Transplantation (LDKT). Toronto, ATC, May 31, 2008.
57. Haririan A, Schweitzer E, Nogueira J, Kukuruga D, Gurk-Turner C, Jacobs S, Drachenberg C, Bartlett S, Cooper M: Long Term Outcomes of Positive Cross Match (PXM) Living Donor Kidney Transplantation (LDKT) after Desensitization. Toronto, ATC, May 31, 2008.
58. Nogueira J, Haririan A, Weir M, Jacobs S, Cooper M: Effects of Smoking on Renal and Patient Outcomes in a Large Single Center Cohort of Recipients of Live Donor Kidney Transplants. Toronto, ATC, May 31, 2008.
59. Campos L, Scalea R, Schweitzer E, Barth R, Cooper M, Bartlett S, Philosophe B: Pediatric “En Block” Renal Transplantation: Single Institution Experience with the use of Grafts from Donors Less Than One Year of Age. Toronto, ATC, May 31, 2008.
60. Schroder N, Cooper M, Welsh C, Haririan A: Psychosocial Screening Practices for Living Kidney Donors (LKD) in the US. Toronto, ATC, May 31, 2008.

Abstracts (Continued):

61. Kukuruga D, Kiangkitiwan B, Cooper M, Beattie R, Hurley H, Kennedy M, Klassen D, Haririan A: The Prevalence of Donor Specific Antibody (DSA) after Kidney transplantation (KT) and Its Associated Risk Factors. Toronto, ATC, June 1, 2008.
62. Butler K, Collins M, Haririan A, Weir M, Barth R, Campos L, Philosophe B, Bartlett S, Cooper M: Inferior Patient Outcomes with Peritoneal Dialysis as a Pre-Transplant Renal Replacement Modality. Toronto, ATC, June 1, 2008.
63. Kramer A, Phelan M, Cooper M, Bartlett S: Simultaneous Bilateral Native Nephrectomy and Living Donor Renal Transplantation Is Successful for Autosomal Dominant Polycystic Kidney Disease: The University of Maryland Experience. Toronto, ATC, June 1, 2008.
64. Munivenkatappa R, Drachenberg C, Papadimitriou J, Kukuruga D, Mccann E, Cooper M, Campos L, Barth R, Schweitzer E, Bartlett S, Philosophe B: High Rate of Graft Loss Associated with C4d Positive Staining in Pancreas Transplantation. Toronto, ATC, June 2, 2008.
65. Sener A, Schweitzer E, Cooper M, Campos L, Bartlett S, Philosophe B, Barth R: Geriatric Recipients of Deceased Donor Renal Transplants Demonstrate Equal Graft Survival to Non-geriatric Populations. Toronto, ATC, June 2, 2008.
66. Scalea J, Nogueira J, Campos L, Haririan A, Barth R, Philosophe B, Bartlett S, Cooper M: Pancreas Transplant Alone (PTA) as an Independent Risk Factor for the Development of Renal Failure. Sydney, AUS, XXII International Congress, August 11, 2008.
67. Sener Alp, Cooper M, Schweitzer E, Campos L, Bartlett S, Philosophe B, Barth R: Geriatric Recipients of Deceased Donor Renal Transplants Demonstrate Equal Graft Survival to Non-Geriatric Populations. Sydney, AUS, XXII International Congress, August 11, 2008.
68. Roelant G, Miller J, Haririan A, Nogueira J, Philosophe B, Bartlett S, Cooper M: Machine Pulsatile Perfusion and its Predictive Value for Delayed Graft Function in Cadaveric Renal Transplants (CRT). Sydney, AUS, XXII International Congress, August 11, 2008.
69. Munivenkatappa R, Schweitzer E, Drachenberg C, McCann E, Dock A, Kukuruga D, Cooper M, Campos L, Barth R, Papadimitriou J, Bartlett S, Philosophe B: C4d+ Antibody Mediated Rejection and Campath Induction are Risk Factors for Graft Loss Following Pancreas Transplantation. Sydney, AUS, XXII International Congress, August 11, 2008.
70. Cooper M, Haririan A, Jacobs S, Phelan M, Philosophe B, Bartlett S, Nogueira J: Predictors of Poor Early Graft Function Following Laparoscopic Donor Nephrectomy (LDN). Sydney, AUS, XXII International Congress, August 11, 2008.
71. Schroder N, Haririan A, Welsh C, Cooper M: Psychosocial Screening and Follow-Up Practices for Living Kidney Donors (LKD) at US Transplant Centers. Sydney, AUS, XXII International Congress, August 12, 2008.

Abstracts (Continued):

72. Scalea J, Miller J, Alexander C, Philosophe B, Barth R, Bartlett S, Cooper M: Volume-Outcome Relationship in the Procurement of Transplantable Organs. Sydney, AUS, XXII International Congress, August 14, 2008.
73. Cooper M, Haririan A, Weir M, Jacobs S, Klassen D, Bartlett S, Nogueira J: Renal Outcomes in African-American Living Kidney Donors. Sydney, AUS, XXII International Congress, August 14, 2008.
74. Barth R, Gurk-Turner C, Klassen D, Cooper M, Schweitzer E, Campos L, Bartlett S, Philosophe B: Successful Alemtuzumab Induction and Steroid Withdrawal in African American and Caucasian Recipients of Renal Transplants. Sydney, AUS, XXII International Congress, August 14, 2008.
75. Sener A, Barth R, Cooper M, Campos L, Schweitzer E, Bartlett S, Philosophe B: HCV+ Renal Transplant Patients Do Not Progress to Liver Cirrhosis Following T-Cell Depletion. Sydney, AUS, XXII International Congress, August 14, 2008.
76. Schroder N, Haririan A, Welsh C, Cooper M: When Family Secrets are Uncovered: Discovery of Misattributed Paternity Information at US Transplant Centers. Sydney, AUS, XXII International Congress, August 14, 2008.
77. Chan L, Hartmann E, Cibrik D, Cooper M, Shaw L: Everolimus (RAD001) Concentration is Associated with Risk Reduction for Acute Rejection in De Novo Renal Transplant Recipients. Phila. PA, ASN, Nov. 2008.
78. Hetterman E, Correa A, McCann E, Rasetto F, Cooper M. A Retrospective Review of Immunosuppression in High-Risk, EBV-mismatch Living Donor Kidney Transplant Recipients. Hershey, PA, 28th Annual Eastern States Conference for Pharmacy Residents and Preceptors, April 29, 2009.
79. Brewer M, Milburn M, Rada E, Goldberg N, Singh D, Cooper M, Silverman R. Benefits of Human Acellular Dermal Matrix for Ventral Hernia Repair in Transplant Patients. Pittsburg, PA, 54th Annual Plastic Surgery Research Council, May 30, 2009.
80. Cooper M, Slakey D, Deering K, Arcona S, McCann E, Rasetto F, Florman S. Outcomes Associated with Dose Manipulations of Enteric-Coated Mycophenolate Sodium (EC-MPS) vs. Mycophenolate Mofetil (MMF) in Renal Transplantation. Boston, MA, American Transplant Congress, May 31, 2009.
81. Cooper M, Sener A, Munivenkatappa R, Singh M, Barth R, Bartlett S, Philosophe B, Haririan A. When Zero Mismatch Means Zero: The Hazards of Our Deceased Donor Allocation System. Boston, MA, American Transplant Congress, June 1, 2009.

Abstracts (Continued):

82. Wainright J, Cooper M, Bolton L, Davis C. The Changing Landscape of Living Kidney Donors in the US. Boston, MA, American Transplant Congress, June 2, 2009.
83. Philosophe B, Tabor C, Jackson A, McCann E, Barth R, Schweitzer E, Cooper M, Fayek S, Bartlett S, Munivenkatappa R. Improving Long Term Outcomes in Recipients of Older Kidneys Utilizing a Pre-Implantation Biopsy Scoring System (MAPI). Boston, MA, American Transplant Congress, June 2, 2009.
84. Sener A, Vanguri P, Munivenkatappa R, Manitpisitkul W, Barth R, Haririan A, Bartlett S, Philosophe B, Cooper M. Expanding the Definition of Extended Criteria Donors: Successful Utilization of 70 Year Old Deceased Donor Kidneys. Boston, MA, American Transplant Congress, June 2, 2009.
85. Munivenkatappa R, Gurk-Turner C, Baig M, Klassen D, Cooper M, Schweitzer E, Fayek S, Bartlett S, Philosophe B, Barth R. Alemtuzumab Induction and Steroid Withdrawal Associated with Low Rejection Rates in African-American Renal Transplant Recipients with Delayed Graft Function. Boston, MA, American Transplant Congress, June 3, 2009.
86. Gurk-Turner C, Baig M, Munivenkatappa R, Klassen D, Cooper M, Schweitzer E, Fayek S, Bartlett S, Philosophe B, Barth R. Superior Renal Allograft Survival and Decreased Rejection with Alemtuzumab Induction Compared to Rabbit Anti-Thymocyte Globulin or Basiliximab. Boston, MA, American Transplant Congress, June 3, 2009.
87. Fayek S, Munivenkatappa R, Cooper M, Barth R, Macovei A, McCann E, Rasetto F, Schweitzer E, Bartlett S, Philosophe B. The Impact of Recipient's Hepatitis C Status on Pattern of Mortality in Kidney/Pancreas Transplants. Boston, MA, American Transplant Congress, June 3, 2009.
88. Langone A, Chan L, Bolin P, McCague K, Wiland A, Cooper M. Conversion from Mycophenolate Mofetil (MMF) to Enteric Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients with Diabetes Mellitus (DM). American Society of Nephrology.
89. Scalea J, Munivenkatappa R, Barth R, Fayek S, Philosophe B, Bartlett S, Cooper M. Risk-Benefit Analysis for the Use of Anticoagulation Protocols Following Pancreas Transplantation Alone (PTA). Venice, Italy, IPITA, Oct 15, 2009.
90. Cooper M, Scalea J, Munivenkatappa R, Barth R, Fayek S, Philosophe B, Bartlett S. Valuable Lessons Learned in Pancreas Re-Transplantation over a 20-year Period. Venice, Italy, IPITA, Oct 15, 2009.
91. Cooper M, Kapur S, Stratta R, D'Alessandro A, Mulgaonkar S, Allison A, Russell M, Knechtle S. Urinary IP-10 Increase Post Renal Transplant is Attenuated by Single IVB of Diannexin, a Novel Ischemia Reperfusion Injury Therapy. San Diego, CA, American Transplant Congress. May 1, 2010.

Abstracts (Continued):

92. Hurley H, Richards T, Nogueira J, Cooper M, Klassen D, Haririan A. Outcome of Acute Antibody-Mediated Rejection after Treatment with Plasmapheresis/IVIg in Renal Allograft Recipients. San Diego, CA, American Transplant Congress. May 1, 2010.
93. Mohamed M, Portocarrero M, Turner C, Cooper M, Klassen D, Haririan A. Insulin Resistance and Secretion in African-American ESRD Patients and Chronic Hepatitis C. San Diego, CA, American Transplant Congress. May 1, 2010.
94. Cooper M, Arcona S, Gifford R, Baillie M, Irish W. Enteric-coated Mycophenolate Sodium (EC-MPS) v. Mycophenolate Mofetil (MMF) Maintenance Immunosuppression: Outcomes Analysis of the UNOS/OPTN Database. San Diego, CA, American Transplant Congress. May 1, 2010.
95. Cooper M, Kapur S, Stratta R, D'Alessandro A, Malgaonkar S, Allison A, Russell M, Knechtle S. Diannexin, a Novel Ischemia/Reperfusion Therapeutic Agent, Reduces Delayed Graft Function (DGF) in Renal Transplant Recipients from Marginal Donors. San Diego, CA, American Transplant Congress. May 2, 2010.
96. Keshtkar-Jahromi M, Sajadi M, Rasetto F, Cooper M, Klassen D, Haririan A. Infectious Complications after Kidney Transplantation: Current Epidemiology and Impact on Graft Outcome. San Diego, CA, American Transplant Congress. May 2, 2010.
97. Pradel F, Bradley-Baker L, Campbell M, Wagner L, Hurley H, Cooper M. Kidney Transplant Patients' Immunosuppressant Drugs Information Needs. San Diego, CA, American Transplant Congress. May 2, 2010.
98. Barth R, Cooper M, Phelan M, Fayek S, Sener A, Bartlett S, Philosophe B. Embryonic-Natural Orifice Transumbilical Endoscopic Surgery (e-NOTES) Donor Nephrectomy: Integration as Standard Approach at a Large Volume Transplant Center. San Diego, CA, American Transplant Congress. May 3, 2010.
99. Metireddy M, Nogueira J, Hakim M, Cooper M, Weir M, Klassen D, Haririan A. Serum Uric Acid, an Independent Risk Factor for Worse Graft Outcomes after Kidney Transplantation. San Diego, CA, American Transplant Congress. May 3, 2010.
100. Munivenkatappa R, Soundararajan S, Malat G, Ranganna K, Wali R, Barth R, Fayak S, Cooper M, Schweitzer E, Papatimitriou J, Drachenberg C, Bartlett S, Kumar M, Philosophe B. Validation of the Maryland Aggregate Pathology Index (MAPI) on Pre-Implantation Biopsies as a Predictor of Graft Outcomes at Two Independent Transplant Centers. San Diego, CA, American Transplant Congress. May 3, 2010.

Abstracts (Continued):

101. Philosophe B, Neuman B, Cooper M, Barth R, Schweitzer E, Fayek S, Bartlett S, Munivenkatappa R. The Maryland Aggregate Pathology Index (MAPI) is Superior to the Kidney Donor Risk Index (KDRI) as a Predictor of Graft Outcome. San Diego, CA, American Transplant Congress. May 3, 2010.

102. Cooper M, Barth R, Haririan A, Jacobs S, Klassen D, Weir M, Bartlett S, Nogueira J. When Asking Too Much Leaves Too Little: An Analysis of Obese Living Kidney Donors To Assess the Risk of Hypertension and Adverse Renal Outcomes at a Single Institution. San Diego, CA, American Transplant Congress. May 3, 2010.

103. Jones H, Nogueira J, Haririan A, Jacobs S, Weir M, Cooper M. The Effect of Living Donor Obesity of Recipient Renal Outcomes. San Diego, CA, American Transplant Congress. May 4, 2010.

104. Adari S, Nogueira J, Haririan A, Weir M, Jacobs S, Cooper M. The Effect of Smoking by Live Kidney Donor on Recipient Renal Outcomes. San Diego, CA, American Transplant Congress. May 4, 2010.

105. Nogueira J, Adari S, Brown E, Haririan A, Jacobs S, Weir M, Cooper M. The Effect of Higher Than Normal Blood Pressure Living Kidney Donors on Recipient Renal Outcomes. San Diego, CA, American Transplant Congress. May 4, 2010.

106. Chisolm-Burns M, Pinsky B, Parker G, Johnson P, Buzinec P, Irwin F, Chakravati P, Svendsen H, Good M, Arcona S, Cooper M. Patient Reported Factors Influencing Adherence to Antirejection Medications. San Diego, CA, American Transplant Congress. May 4, 2010.

107. Cooper M, Phelan M, Barth R, Fayek S, Bartlett S, Philosophe B. Living Kidney Donor Relationships in Caucasian and African American Populations and Implications for Targeted Donor Education Programs. Vancouver, CA, XXIII International Congress of the Transplantation Society. Aug 16, 2010.

108. Munivenkatappa R, Barth R, Cooper M, Philosophe B. A Banff cv2 Lesion In a Pre-Implantation Biopsy Is the Best Predictor of Delayed Graft Function Following Transplantation. Vancouver, CA, XXIII International Congress of the Transplantation Society. Aug 16, 2010.

109. Cooper M, Kapur S, Stratta R, D'Alessandro A, Mulgaonkar S, Allison A, Russell M, Knechtle S. Treatment with Diannexin Post-Reperfusion Decreases DGF and Improves GFR in Renal Transplant Recipients of Marginal Kidney Donors. Vancouver, CA, XXIII International Congress of the Transplantation Society. Aug 16, 2010.

110. Fayek S, Cooper M, Barth R, Schweitzer E, Bartlett S, Philosophe B. The Influence of Donor Type on Ureteral Complications after Kidney Transplantation. Vancouver, CA, XXIII International Congress of the Transplantation Society. Aug 17, 2010.

Abstracts (Continued):

111. Munivenkatappa R, Barth R, Fayek S, Cooper M, Schweitzer E, Bartlett S, Philosophe B. Validation of the Maryland Aggregate Pathology Index (MAPI) on Pre-Implantation Biopsies As a Predictor of Graft Outcome at Two Independent Transplant Centers. Vancouver, CA, XXIII International Congress of the Transplantation Society. Aug 18, 2010.

112. Philosophe B, Barth R, Cooper M, Munivenkatappa R. The Maryland Aggregate Pathology Index (MAPI) is Superior to the Kidney Donor Risk Index (KDRI) As a Predictor of Graft Outcome. Vancouver, CA, XXIII International Congress of the Transplantation Society. Aug 19, 2010.

113. Cooper M, Rasetto F, Philosophe B, Nogueira J. A 12-month Single Center Evaluation of GI-complications In Renal Transplant Recipients Initiated on Mycophenolic Acid Therapy. Vancouver, CA, XXIII International Congress of the Transplantation Society. Aug 19, 2010.

114. Barth R, Cooper M, Phelan M, Fayek S, Bartlett S, Philosophe B. Safe and Routine Application of LaparoEndoscopic Single Site (LESS) Donor Nephrectomies: Experience with 60 Cases. Vancouver, CA, XXIII International Congress of the Transplantation Society. Aug 19, 2010.

115. Barth R, Phelan M, Cooper M, Fayek S, Bartlett S, Philosophe B. LaparoEndoscopic Single Site (LESS) Donor Nephrectomy as Standardized Surgical Approach: Experience with 60 Cases. American College of Surgeons, October, 2010.

116. Chudgar A, Daly B, Lee B, Cooper M. Pre-operative CT Angiography of Prospective Renal Transplant Recipients: Evaluation of Safety of Iso-osmolar Non-ionic Intravascular Contrast, Imaging Findings and Effects on Management in a Pre-dialysis Patient Cohort. RSNA, 2010.

117. Cooper M, Smith D, Chudgar A, Daly B, Bartlett S. An Ounce of Prevention is Worth a Pound of Cure: The Role of Pre-operative CT Angiography in Living Donor Renal Transplant Recipients. Philadelphia, PA, American Transplant Congress. April 30, 2011.

118. Philosophe B, Bromberg J, Barth R, Fayek S, Schweitzer E, Cooper M, Bartlett S, Munivenkatappa R. Improving Utilization of >70 Year Old Donor Kidneys in the United States. Philadelphia, PA, American Transplant Congress. May 1, 2011.

119. Philosophe B, Manitpitsikul, Wilson N, Barth R, Cooper M, Bromberg J, Schweitzer E, Fayek S, Bartlett S, Munivenkatappa R. Sirolimus Conversion Improves Outcome of Marginal Kidneys with Intermediate Maryland Aggregate Pathology Index (MAPI) Scores. Philadelphia, PA, American Transplant Congress. May 1, 2011.

120. Fayek S, Keenan J, Haririan A, Cooper M, Barth R, Schweitzer E, Bromberg J, Bartlett S, Philosophe B. The Value of Ureteral Stents in Kidney Transplantation. A Large Single Center 5-Year Experience. Philadelphia, PA, American Transplant Congress. May 1, 2011.

Abstracts (Continued):

121. Highbaugh M, Hurley H, Nogueira J, Barth R, Bartlett S, Cooper M. Outcomes of Renal Transplantation in HIV-Positive Recipients Following Basiliximab Induction and Triple Drug Immunosuppression: Is Too Little Costing Too Much? Philadelphia, PA, American Transplant Congress. May 3, 2011.

122. Manitpisitkul W, Wilson N, Nicholas S, Drachenberg C, Kukuruga D, Cooper M, Bartlett S, Haririan A. Kidney Transplant Outcome with Thymoglobulin/Rituximab Induction in Patients with Pre-Transplant Low-Level DSA. Philadelphia, PA, American Transplant Congress. May 3, 2011.

123. Barth R, Cooper M, Phelan M, Fayek S, Bartlett S, Philosophe B. Technique and Learning Curve with Adopting Single Port Donor Nephrectomy as Standard Approach. Philadelphia, PA, American Transplant Congress. May 3, 2011.

124. Scalea, J, Barth R, Fayek S, Bromberg J, Philosophe B, Bartlett S, Cooper M. Metabolic Syndrome and Solitary Pancreas Transplantation: Role for Statin Therapy. International Pancreas and Islet Transplantation Association. June 3, 2011.

125. Cooper M, Scalea J, Barth R, Fayek S, Bromberg J, Philosophe B, Bartlett S. Portal v. Systemic Drainage of Solitary Pancreas Transplantation: New Views on Old Concepts. International Pancreas and Islet Transplantation Association. June 3, 2011.

126. Scalea J, Barth R, Fayek S, Bromberg J, Philosophe B, Bartlett S, Cooper M. Pancreatic Re-transplantation Outcome Compares Favorably to Primary Pancreas Transplantation. International Pancreas and Islet Transplantation Association. June 2, 2011.

127. Smith D, Daly B, Chudgar A, Cooper M. Screening of Prospective Renal Transplant Recipients with CT Angiography: Imaging Findings, Safety, and Implications for Patient Management. American Roentgen Ray Society 2011.

128. Wiseman A, McCague K, Kim Y, Geissler F, Cooper M. Therapeutic Drug Monitoring of Everolimus Reduces the Risk of Proteinuria Over 24 Months Following Kidney Transplant. 2011 AST Annual Scientific Exchange. San Antonio, TX, Dec 4, 2011.

129. Wiseman A, McCague K, Kim Y, Geissler F, Cooper M. Early Post-Transplant Proteinuria as a Prognostic Factor for Long-Term GFR and Allograft Survival. 2011 AST Annual Scientific Exchange. San Antonio, TX, Dec 4, 2011.

130. Goldschen L, Munivenkatappa R, Phelan M, Cooper M, Fayek S, Philosophe B, Bartlett S, Barth R. Single-Port Nephrectomy Provides Improved Donor Satisfaction. 2012 ASTS 12th Annual State of the Art Winter Symposium. Miami Beach, FL, Jan 13, 2012.

Abstracts (Continued):

131. Cooper M, Geissler F, Kim Y, Wiseman A. Therapeutic Drug Monitoring Of Everolimus Reduces Early Post-Transplant Proteinuria- A Prognostic Factor For Long Term Glomerular Filtration Rate (Gfr) And Kidney Allograft Survival. 2012 Academic Surgical Congress. Las Vegas, NV, Feb 16, 2012.

132. Smith D, Cooper M, Chudgar A, Daly B. Screening of Prospective Transplant Recipients with CT Angiography: Imaging Findings, Safety, and Implications for Patient Management. 2012 American Roentgen Ray Society. Vancouver, April 30, 2012.

133. Campbell ML, Pradel FG, Bradley-Baker L, Mullins CD, Hurley H, Cooper M. Role of Health Literacy on Kidney Transplant Patients Immunosuppressant Drugs Information Needs. International Society for Pharmacoeconomics and Outcomes Research 17th Annual International Meeting, Washington, D.C. June 2 – 6, 2012.

134. Grafals M, Cooper M, Verbese J, Vucci J, Javaid B, Timofeeva O, Rosen-Bronson S. Clinical Outcomes of Paired Kidney Exchange for Highly Sensitized Renal Transplant Recipients. 2013 American Transplant Congress, Seattle, WA, May 18, 2013.

135. Verbese J, Cooper M, Andrews P, Rogalsky D, Moody P, Chen Y. Using Non-Invasive, Real-Time Imaging Techniques to Assess the Status of Donor Kidneys. 2013 American Transplant Congress, Seattle, WA, May 19, 2013.

136. Verbese J, Grafals M, Cooper M, Moore J, Ghasemian S, Nilubol C, Javaid B. Evolving Trends in Living Donor Uninephrectomy Techniques and Impact on Post-Transplant Outcomes: A Review of the US National Cohort. 2013 American Transplant Congress, Seattle, WA, May 20, 2013.

137. Scalea J, Munivenkatappa R, Whitlow V, Neuman B, Fayek S, Cooper M, Philosophe B. Accelerated Hepatic Fibrosis after Renal Transplantation: Long-Term Outcomes in HCV+ Patients. 2013 American Transplant Congress, Seattle, WA, May 20, 2013.

138. Peddi VR, Ratner L, Cooper M, Squires EC, Erlich SS. Treatment with QPI-002, a Short Interfering (SI) RNA for the Prophylaxis of Delayed Graft Function. 2014 World Transplant Congress, San Francisco, CA July 28, 2014.

139. Incompatible Kidney Transplantation Risk and Its Relationship to CMS Regulation: A Multi-Center Study. Orandi B, Garonzik-Wang J, Massie A, Cooper M, Montgomery R, Segev D. 2014 World Transplant Congress, San Francisco, CA July 29, 2014.

140. Effect of Liver Transplant on HLA Sensitization. Grafals M, Desai C, Timofeeva O, Rosen-Bronson S, Verbese J, Gilbert A, Li D, Cooper M, Fishbein T. 2014 World Transplant Congress, San Francisco, CA July 30, 2014.

141. Shorter Waitlist Time for HCV+ Renal Allografts Improves Long-Term Graft Survival Without Associated Progression of Clinical Liver Disease. Scalea J, Barth R, Munivenkatappa R, Cooper M, Whitlow V, Philosophe B, LaMattina J. 2014 World Transplant Congress, San Francisco, CA July 31, 2014.
142. Looking Behind the Curtain: Pre-Transplant Mismatched Eplet Load May Better Predict Increases in Post-Transplant DSA. Timofeeva O, Verbese J, Li D, Grafals M, Moore J, Ghasemian S, Weems P, Cooper M, Rosen-Bronsen S. 2014 World Transplant Congress, San Francisco, CA July 27, 2014.
143. Bortezomib Induced Peripheral Neuropathy in the Treatment of Renal Allograft Antibody Mediated Rejection. Weems P, Gilbert A, Cooper M, Moore J. 2014 World Transplant Congress, San Francisco, CA July 27, 2014.
144. Kidney Transplant Wait List Management Optimization. Grafals M, Rogers M, Weems P, Moore J, Verbese J, Gilbert A, Gonzales E, Ghasemian S, Zwierski D, Fishbein T, Cooper M. 2014 World Transplant Congress, San Francisco, CA July 27, 2014.
145. Mismatched Eplets in HLA Antigens May Predict Development of De Novo Donor Specific Antibody in Kidney Transplant Recipients. Verbese J, Timofeeva O, Li D, Javaid B, Grafals M, Gilbert A, Rosen-Bronson S, Cooper M. 2014 World Transplant Congress, San Francisco, CA July 28, 2014.
146. Recurrence Without Reduced Survival: The Risk of Kidney Allograft Failure Due to Recurrent IgA Nephropathy. Gilbert A, Cooper M, Verbese J, Weems P, Ghasemian S, Moore J, Grafals M, Nilubol C, Moore J, Javaid B. 2014 World Transplant Congress, San Francisco, CA July 28, 2014.
147. Cause and Effect: Membranoproliferative Glomerulonephritis Type 1 and Type II Recur Frequently and Result in Significant Graft Loss. Gilbert A, Cooper M, Verbese J, Weems P, Ghasemian S, Grafals M, Nilubol C, Javaid B. 2014 World Transplant Congress, San Francisco, CA July 28, 2014.
148. The Benefits of a Well Functioning Allograft: Poorer Graft Function After Renal Transplantation Predisposes to Higher Rates of CMV Viremia. Gilbert A, Ko E, Abi-Nader M, Weems P, Ghasemian S, Moore J, Verbese J, Grafals M, Cooper M, Javaid B. 2014 World Transplant Congress, San Francisco, CA July 30, 2014.

Invited Publications:

1. Cooper M. National Kidney Foundation's End the Wait Campaign – A Physician's Perspective 2009.
2. Manipiskitul W, Cooper M. Mycophenolic acid agents: is enteric coating the answer? *Trans Research Risk Mgmt* 2010.
3. Cooper M, Forland C. The Elderly As Recipients of Living Donor Kidneys: How Old is Too Old? *Curr Opin Trans* 16(2): 250-5, 2010.
4. Dew MA, Cooper M. Successful Follow-up of Living Donors: Strategies to Make it Happen. *Prog Trans* 21(2): 94-96, 2011.
5. Invited Critique – Just Because You Can, Doesn't Mean You Should...Because Many of Us Really Can't! *Arch Surg* 146(7): 850, 2011.
6. Scalea J, Cooper M. Surgical Strategies for Type 2 Diabetes. *Transplant Rev* 2011.
7. Scalea J, Cooper M. Current Status of Kidney/Pancreas Combined Transplantation. *J Intens Care Med* 2011.

Book Chapters:

1. Cooper M, Hawxby A. Vascular Access. In: Current Surgical Therapy, 8th Edition. St. Louis, MO: Mosby-Year Book, Inc, 2004: 828-830.
2. Bartlett S, Cooper M. Expanded Criteria Donors. In: Principles of Transplantation. Wiley and Sons, 2012
3. Barth R, Cooper M. Single-Site Minimally Invasive Surgery: What is Currently Possible? In: Current Surgical Therapy, 11th Edition. Elsevier, Inc. 2013
4. Verbese J, Cooper M. Paired Kidney Exchange

Oral Presentations:

1. Myocardial Nuclear Factor KappaB (NF-κB) Activity and Nitric Oxide Production in Rejecting Cardiac Allografts
 - The American Society of Transplant Surgeons' 23rd Annual Scientific Meeting. Chicago, IL. May, 1997.
Milwaukee Academy of Surgeons Resident Research Presentation Night. Milwaukee, WI. March, 1997.
 - MCW Department of Surgery Clinic Day. Milwaukee, WI. April, 1997.
2. Effects of Nitric Oxide Scavenging and Inhibition of NF-κB Activity on Cardiac Allograft Survival. Surgical Forum, American College of Surgeons' 83rd Annual Clinical Congress. Chicago, IL. October, 1997.
3. Long Term Allograft Survival with Nitric Oxide Scavenging. Wisconsin Surgical Society Annual Fall Meeting. Madison, WI. October, 1997.
4. Antioxidant Therapy with Low Dose Cyclosporine Enhances Allograft Survival and Promotes Tolerance. Medical College of Wisconsin Robert E. Condon Research Awards. Milwaukee, WI. June, 1998.
5. Expanded Criteria Donors. ABC's of Renal Transplantation – CME course. Towson, MD. Feb. 2004.
6. Positive Crossmatch and ABO-incompatible Kidney Transplantation. Canadian Society of Xenotransplantation. Ontario, Canada. May 2004.
7. Teaching Residents about Palliative Care. Palliative Care: What Every Surgeon Needs to Know. Baltimore, MD. May, 2005.
8. Laparoscopic Donor Nephrectomy for Transplantation: 10 Years and 1000 Consecutive Cases. World Transplant Congress. Boston, MA. July, 2006.
9. Outcomes Following Vascular Reconstruction for 1000 Consecutive Laparoscopic Donor Nephrectomies. World Transplant Congress. Boston, MA. July, 2006.
10. Living Kidney Donor Relationship in Caucasian and African-American Populations and Implications For Targeted Donor Education Programs. Academic Surgical Congress. Phoenix, AZ, Feb, 2007.
11. Transplant 101: Background for Transplant Nursing Professionals. Baltimore, MD. May 2007.

Oral Presentations (Continued):

12. Impact of Induction Agents on Renal Recipient Outcomes of the First 1000 Laparoscopic Donor Nephrectomies at a Single Institution. American Transplant Congress. San Diego, CA, May 2007.
13. Renal Transplantation in ESRD with Cirrhosis. ASTS/AST Combined Kidney/Liver Transplant Consensus Conference. Chicago, IL. Sept. 2007.
14. New Life. New Challenges. Life Following Transplantation. Transplant Patient Support Group. Baltimore, MD. Nov. 2007.
15. As Kidney Transplantation Moves Toward 2009: A View of Potential Advances and the Ongoing Challenges. Novartis Advisory Board Meeting. Dallas, TX. Nov. 2007.
16. Successful Simultaneous Bilateral Native Nephrectomy and Living Donor Renal Transplantation for Autosomal Dominant Polycystic Kidney Disease. Academic Surgical Congress. Huntington Beach, CA, Feb. 2008.
17. Risk Factors for Delayed Graft Function in Living Donor Transplantation. American Transplant Congress. Toronto, June 2008.
18. Shifting Focus Toward Long-Term Outcomes in Kidney Transplantation. Novartis Advisory Board Meeting. Chicago, IL, June 2008.
19. Approaches to Optimizing Immunosuppression Regimens to Improve Long-Term Outcomes. Novartis Advisory Board Meeting. Chicago, IL, June 2008.
20. Outcomes of African-American Living Kidney Donors. International Transplant Congress. Sydney, AUS, Aug. 2008.
21. Volume-Outcome Relationships in the Procurement of Transplantable Deceased Donor Organs. Academic Surgical Congress. Fort Myers, Florida, Feb. 2009.
22. Outcomes Associated with Dose Manipulations of Enteric-Coated Mycophenolate Sodium (EC-MPS) vs. Mycophenolate Mofetil (MMF) in Renal Transplantation. American Transplant Congress. Boston, June 2009.
23. When Zero-Mismatch Means Zero: The Hazards of Our Deceased Donor Allocation System. American Transplant Congress. Boston, June 2009.
24. Valuable Lessons Learned in Pancreas Re-Transplantation over a 20-year Period. IPITA. Venice, Italy, Oct 2009.

Oral Presentations (Continued):

25. Diannexin, a Novel Ischemia/Reperfusion Therapeutic Agent, Reduces Delayed Graft Function (DGF) in Renal Transplant Recipients from Marginal Donors. San Diego, CA, American Transplant Congress. May 2, 2010.
26. When Asking Too Much Leaves Too Little: An Analysis of Obese Living Kidney Donors To Assess the Risk of Hypertension and Adverse Renal Outcomes at a Single Institution. San Diego, CA, American Transplant Congress. May 3, 2010.
27. Living Kidney Donor Relationships in Caucasian and African American Populations and Implications for Targeted Donor Education Programs. Vancouver, CA, XXIII International Congress of the Transplantation Society. Aug 16, 2010.
28. Treatment with Diannexin Post-Reperfusion Decreases DGF and Improves GFR in Renal Transplant Recipients of Marginal Kidney Donors. Vancouver, CA, XXIII International Congress of the Transplantation Society. Aug 16, 2010.
29. A 12-month Single Center Evaluation of GI-complications In Renal Transplant Recipients Initiated on Mycophenolic Acid Therapy. Vancouver, CA, XXIII International Congress of the Transplantation Society. Aug 19, 2010.
30. Portal v. Systemic Drainage of Solitary Pancreas Transplantation: New Views on Old Concepts. Prague, Czech Republic. International Pancreas and Islet Transplantation Association. June 3, 2011.
31. Incidence of Wound Events and Lymphocele Formation with *De Novo* Everolimus Use: The Result of 3 RCTs. Boston, MA, American Transplant Congress. June 1, 2012.

Published Multimedia:

1. Maryland Health Today – Living Kidney Donors. May 2008.
2. PeerView Press - Comparing MPAs for Renal Transplant Recipients In a Real World Setting: An Expert’s Perspective. www.peerviewpress.com/n13 March 2010.
3. ‘Ask A Doc’ – Georgetown University Hospital Patient Information Program. Feb. 2013.

Invited Presentations:

1. Status of Living Donor Follow-up. Advisory Committee on Transplantation. Rockville, MD Nov. 2008.
2. Mycophenolic Acid in Solid Organ Transplantation. Chinese Society of Transplantation. Beijing, China, April 2009.
3. Living Donor Nephrectomy and Outcomes. UMMS Transplant Preceptorship, Baltimore, MD, May 2009.
4. In the Beginning, There Were Living Donors... American Foundation for Donation and Transplantation Living Kidney Donation Conference. Nashville, TN, Oct 8-9, 2009.
5. Understanding the Risks and Benefits of Living Donation. American Foundation for Donation and Transplantation Living Kidney Donation Conference. Nashville, TN, Oct 8-9, 2009.
6. Metabolic Surgery for Non-Obese Patients with Type 2 Diabetes Mellitus. IPITA. Venice, Italy, Oct 13, 2009.
7. Current Status of the OPTN's Progress in Revising Living Donor Policies. *Transplant News* Webinar. October 22, 2009.
8. Living Donor Transplantation. University of Maryland Endocrinology Grand Rounds. Oct 29, 2009.
9. Introduction to Transplantation. Centers for Medicare and Medicaid Services, Transplant Center Surveyor Training. Baltimore, MD. December 8, 2009.
10. Working Together: The OPO and the Transplant Center. Centers for Medicare and Medicaid Organ Procurement Organization Surveyor Training. Baltimore, MD. Jan. 26, 2010.
11. Transplant Surgery: The Surgeon's Perspective. Bristol-Myers-Squibb Medical Team Training Session. Trenton, NJ. April 21, 2010.
12. Strategies to Improve Living Donor Follow-up. UNOS Transplant Management Forum. Orland, FL. April 22, 2010.
13. Current Status of UNOS Paired Kidney Exchange Program. UNOS Organ Procurement Organization National Meeting. Baltimore, MD. June 18, 2010.
14. Living Donor Transplantation. Living Legacy Foundation OPO. Baltimore, MD. June 30, 2010.

Invited Presentations (Continued):

15. Transplant Updates. Maryland's NP Educational Program. Baltimore, MD. November 9, 2010.
16. Life as a Transplant Surgeon. University of Maryland's Medical Student Surgical Interest Group. Baltimore, MD. March 9, 2011.
17. Kidney Allocation and Transplantation. St. Joseph's Hospital Medical Grand Rounds. Towson, MD. March 16, 2011.
18. Cardiac Workup for Kidney and Pancreas Transplant Candidates. University of Maryland Anesthesia Grand Rounds. Baltimore, MD. April 7, 2011.
19. Living Donor Nephrectomy. American Foundation for Donation and Transplantation Living Kidney Donation Conference. Bal Harbour, Fl. May 20, 2011.
20. What Should be Considered in Selecting an MPA Agent. Today and Tomorrow in Transplantation (T3 Symposium). Seoul, Korea May 28, 2011.
21. The 'Value' of Living Kidney Donation. Loyola College. Towson, MD. Jan 19, 2012.
22. A Day in the Life of a Transplant Surgeon. MD Mindset. San Diego, CA. Feb 1, 2012.
23. The Past, the Present, and the Future of Kidney Transplantation. The DC Chapter of the International Transplant Nurses' Society. Washington, DC. Dec. 13, 2012.
24. Growing Competitive Programs in the Current Environment. 2013 American Transplant Congress, Seattle, WA, May 21, 2013.
25. Clinical Trials for Attenuating Ischemia Reperfusion Injury. 2013 American Transplant Congress, Seattle, WA, May 22, 2013.
26. Steroid Avoidance Protocols in Kidney Transplantation. Sanofi Transplant Leadership Summit, Prague Oct. 4, 2013.
27. Pancreas Transplantation for Type 1 and Type 2 Diabetes. Transplant Fellow's Symposium, Washington, DC, Oct. 9, 2013.
28. Kidney Transplantation for the OR Professional. Georgetown University Hospital OR Inservice, Washington, DC, Oct 24, 2013.